Full metadata record
DC FieldValueLanguage
dc.creatorMartín, M. (Miguel)-
dc.creatorGuerrero-Zotano, A. (Angel)-
dc.creatorMontero, Á. (Ángel)-
dc.creatorJara, C. (Carlos)-
dc.creatorFilipovich, E. (Elena)-
dc.creatorRojo-Todo, F. (Federico)-
dc.creatorMoreno, F. (Fernando)-
dc.creatorGarcía-Sáenz, J.Á. (José Ángel)-
dc.creatorAlés, J.E. (José Enrique)-
dc.creatorChacón, J.I. (José Ignacio)-
dc.creatorCruz, J. (Josefina)-
dc.creatorGimenez, J. (Julia)-
dc.creatorCruz-Merino, L. (Luis) de la-
dc.creatorAlgara, M. (Manel)-
dc.creatorSantisteban, M. (Marta)-
dc.creatorLópez-Tarruella, S. (Sara)-
dc.date.accessioned2023-05-23T07:26:17Z-
dc.date.available2023-05-23T07:26:17Z-
dc.date.issued2020-
dc.identifier.citationMartín, M. (Miguel); Guerrero-Zotano, A. (Angel); Montero, Á. (Ángel); et al. "GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain". The Oncologist. 25 (9), 2020, e1339 - e1345es
dc.identifier.issn1083-7159-
dc.identifier.urihttps://hdl.handle.net/10171/66323-
dc.description.abstractBreast cancer (BC) is the most common cancer in women in Spain. During the COVID-19 pandemic caused by the SARSCoV-2 virus, patients with BC still require timely treatment and follow-up; however, hospitals are overwhelmed with infected patients and, if exposed, patients with BC are at higher risk for infection and serious complications if infected. Thus, health care providers need to evaluate each BC treatment and in-hospital visit to minimize pandemic-associated risks while maintaining adequate treatment efficacy. Here we present a set of guidelines regarding available options for BC patient management and treatment by BC subtype in the context of the COVID-19 pandemic. Owing to the lack of evidence about COVID-19 infection, these recommendations are mainly based on expert opinion, medical organizations’ and societies’ recommendations, and some published evidence. We consider this a useful tool to facilitate medical decision making in this health crisis situation we are facing.es_ES
dc.description.sponsorshipMiguel Martín: Roche, PUMA, Novartis (RF), AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Daiichi Sankyo, Pfizer (C/A), AstraZeneca, Amgen, Roche/ Genentech, Novartis, Pfizer (H); Fernando Moreno: Pfizer, Merck Sharp & Dohme, Novartis, Roche/Genentech, AstraZeneca (C/A), Pfizer, Roche (H), Roche/Genentech, Novartis, Pfizer (travel support), Pfizer, AstraZeneca (RF [to institution]); Jose Angel García Sáenz: Novartis, Celgene, Eli Lilly, EISAI, AstraZeneca (H), Novartis, Roche, Pfizer (travel support), Pfizer, AstraZeneca (RF [to institution]); José Ignacio Chacón: Roche Farma, Pfizer, Eisai, Eli Lilly, Novartis (H); Josefina Cruz: Glaxo, AstraZeneca, Roche, Novartis, PharmaMar, Eisai, Eli Lilly, Celgene, Astellas, Amgen, Pfizer (H), AstraZeneca, Roche, Novartis, PharmaMar, Eisai, Eli Lilly, Celgene, Astellas, Amgen, Glaxo, Pfizer (C/A); Luis de la Cruz Merino: MSD-Merck, Roche Farma, Bristol-Myers Squibb, Pierre-Fabré, Amgen, Novartis (C/A), MSD-Merck, Roche Farma, Bristol-Myers Squibb, Amgen (H), Bristol-Myers Squibb, Roche Farma, MSD-Merck, Celgene (RF). The other authors indicated no financial relationships. (C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/ inventor/patent holder; (SAB) Scientific advisory boardes_ES
dc.language.isoenges_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectBreast canceres_ES
dc.subjectPandemices_ES
dc.subjectCOVID-19es_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectExpert recommendationses_ES
dc.titleGEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spaines_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.es_ES
dc.identifier.doi10.1634/theoncologist.2020-0363-
dadun.citation.endingPagee1345es_ES
dadun.citation.number9es_ES
dadun.citation.publicationNameThe Oncologistes_ES
dadun.citation.startingPagee1339es_ES
dadun.citation.volume25es_ES

Files in This Item:
Thumbnail
File
oncolo_25_9_e1339.pdf
Description
Size
441.22 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.